Biosimilars offer cost-saving advantages, and can help maintain clinical efficacy.

Demographics of Online Attendees

**Biosimilar Product**
- Analogous to a biological product that is highly similar and has no clinically meaningful differences from an existing FDA-approved reference product.
- An interchangeable product is a biosimilar product that meets additional requirements.

**Interchangeable Product**
- An interchangeable product is a biosimilar product that can be alternated with reference product with no change in safety or efficacy.

Q & A

**Q.** A biosimilar is:
- A biologic (Correct)
- Manufactured differently from the reference product (Correct)
- Less similar in safety and efficacy (Correct)
- Has the same mechanism of action (Correct)

**Q.** What must a biosimilar demonstrate in order to be given the designation of being interchangeable by the US FDA?

- It must have the same amino acid sequence as the reference drug (Correct)
- It can be alternated with reference product with no change in safety or efficacy (Correct)
- It is given the designation by the US FDA when approved as a biosimilar (Correct)
- No answer

**Q.** Interchangeability has been granted for which of the following biosimilars?

- Zarzio, 23
- Granix, 12
- Mvasi, 9
- Zirabev, 3
- None of the above (Correct answer)

References

1. FDA. Biosimilars. Available at: https://www.fda.gov/drugs/guidance-compliance-regulatory-information-drugs/biosimilars.

This project is funded through an unrestricted education grant from Pfizer Inc.